Milestone Pharmaceuticals Inc. 8K

Milestone Pharmaceuticals reported Q1 2026 results, detailing the early U.S. launch traction of CARDAMYST, key global and clinical development milestones for etripamil, and a strengthened cash position expected to fund operations into the second half of 2027 despite a continued net loss.

On May 13, 2026, Milestone Pharmaceuticals Inc. reported its financial results for the quarter ended March 31, 2026 and provided a corporate update, highlighting the early commercial progress of CARDAMYST (etripamil) nasal spray for PSVT following its mid‑February 2026 U.S. launch, including approximately 600 prescriptions filled for 560 patients, about 400 unique prescribers, and Express Scripts’ addition of CARDAMYST to its commercial national formularies effective March 27, 2026. The company also noted advancement of its global strategy with acceptance of the etripamil PSVT marketing authorization application by the European Medicines Agency, a decision on which is expected by the first half of 2027, and Everest Medicines’ acquisition of rights from Corxel Pharmaceuticals to develop, manufacture, and commercialize CARDAMYST in Greater China, where an NDA is already under review by the NMPA. Milestone announced initiation of a Phase 3 registrational program evaluating self‑administered etripamil for atrial fibrillation with rapid ventricular rate (AFib‑RVR), with first patient enrollment anticipated in the second half of 2026 and an intent to pursue an sNDA leveraging the existing PSVT safety and efficacy package. Financially, the company reported cash, cash equivalents, and short‑term investments of $184.2 million as of March 31, 2026 (up from $106.0 million at December 31, 2025), product revenue of $0.2 million from initial CARDAMYST sales, total operating expenses of $23.9 million, and a net loss of $26.1 million ($0.20 per share), and stated that its current capital is expected to fund operations into the second half of 2027, including commercial activities and the AFib‑RVR Phase 3 trial.

Filing Facts

CIK

1408443

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-059780

Alert Tier

6